Kane Biotech Inc. has completed its U.S. Food and Drug Administration 510(k) clearance submission for revyve Antimicrobial Wound Cleanser, marking the company's third product in its revyve wound care line. The submission positions Kane to capture a portion of the U.S. wound cleanser market, which exceeded $200 million in 2024.
The revyve Antimicrobial Wound Cleanser is designed as a companion product to Kane's existing FDA 510(k) cleared revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray. The cleanser will serve as part of routine wound management protocols, providing irrigation to cleanse acute and chronic wounds while decreasing bacterial load and removing loose material. The formulation is based on the company's established revyve Antimicrobial Wound Gel.
Clinical Evidence Supports Product Efficacy
Kane Biotech presented compelling clinical data at the Symposium on Advanced Wound Care (SAWC) Fall conference in Las Vegas, demonstrating the effectiveness of its revyve products in challenging wound care scenarios. The presentations included two significant case studies that highlight the therapeutic potential of the company's antimicrobial wound gel technology.
In the first case study, revyve Antimicrobial Wound Gel was used to treat a two-year-old non-healing Stage 4 sacral ulcer in an elderly patient who initially presented with a pain score of 10/10. Previous treatments had included daily dressing changes using silver-based antimicrobial agents and gelling fiber wound fillers without success. The deep cavity wound required a thermoreversible gel to cover all wound surfaces effectively.
Treatment with revyve and daily dressing changes resulted in dramatic pain reduction, with pain scores dropping to 0. Over three weeks, the wound size decreased significantly, and a reduction in Klebsiella pneumonia cultures was observed throughout the treatment course. The patient continued dressing changes with revyve over the two-month study period.
Breakthrough Results in Venous Leg Ulcer Treatment
The second case study involved an elderly female patient with a two-year-old non-healing venous leg ulcer. The full-thickness wound presented with slough, eschar, and necrotic tissue alongside granulation tissue, with an initial pain score of 5/10. Treatment combined revyve Antimicrobial Wound Gel with a vibrational debridement tool.
Pain levels decreased progressively during treatment, with the patient reporting a pain score of 0 from week three onward. The wound demonstrated progressive healing with a 60% reduction in wound size over eight weeks, accompanied by decreased discharge. This case study illustrates the potential for revyve products to transform non-healing wounds into healing wounds when combined with appropriate debridement techniques.
Addressing Biofilm-Related Antibiotic Resistance
Kane Biotech's revyve product line specifically targets biofilms, which represent one of the main contributors to antibiotic resistance in wounds. This resistance leads to serious clinical outcomes and significant healthcare costs. The revyve formulation addresses both biofilms and wound bacteria, offering a dual mechanism of action that differentiates it from traditional wound care products.
The company's existing revyve Antimicrobial Wound Gel has received Health Canada approval in addition to FDA 510(k) clearance, while the revyve Antimicrobial Wound Gel Spray has also achieved FDA 510(k) clearance. These regulatory approvals provide a foundation for the commercial expansion of the revyve product line.
Market Expansion Strategy
Dr. Robert Huizinga, Kane Biotech's Interim Chief Executive Officer, presented the clinical data at SAWC and used the conference opportunity to meet with potential U.S. distributors. The company's participation in this multidisciplinary wound care community, which includes physicians, nurses, podiatrists, physical therapists, researchers, and administrators, positions Kane to expand its market presence in the advanced wound care sector.
The completion of the FDA 510(k) submission for the wound cleanser represents a strategic expansion of Kane's product portfolio, potentially allowing healthcare providers to implement a comprehensive revyve-based wound care protocol that includes cleansing, treatment, and ongoing management components.
